Natus Medical Inc. (NASDAQ:BABY) will be issuing its Q316 quarterly earnings data on Wednesday, October 19th.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings data on Wednesday, July 20th. The company reported $0.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.03. The company had revenue of $96 million for the quarter, compared to analysts’ expectations of $92.71 million. Natus Medical had a net margin of 10.20% and a return on equity of 13.82%. The business’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.34 EPS. On average, analysts expect Natus Medical to post $1.58 EPS for the current fiscal year and $1.75 EPS for the next fiscal year.
Natus Medical Inc. (NASDAQ:BABY) opened at 40.65 on Monday. The stock has a 50 day moving average of $41.01 and a 200 day moving average of $37.02. The firm has a market cap of $1.32 billion, a PE ratio of 35.04 and a beta of 0.78. Natus Medical Inc. has a 52 week low of $29.54 and a 52 week high of $51.05.
Several equities research analysts have recently weighed in on BABY shares. Zacks Investment Research raised shares of Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a report on Thursday, July 7th. Benchmark Co. started coverage on shares of Natus Medical in a report on Tuesday, October 4th. They issued a “buy” rating and a $55.00 target price on the stock. Finally, Raymond James Financial Inc. raised shares of Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 target price on the stock in a report on Tuesday, September 13th.
In related news, insider James B. Hawkins purchased 10,000 shares of Natus Medical stock in a transaction that occurred on Wednesday, September 28th. The shares were acquired at an average price of $38.48 per share, for a total transaction of $384,800.00. Following the transaction, the insider now directly owns 459,725 shares in the company, valued at $17,690,218. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.80% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Fund Advisors increased its position in shares of Natus Medical by 4.6% in the second quarter. BlackRock Fund Advisors now owns 2,250,439 shares of the company’s stock valued at $85,067,000 after buying an additional 99,981 shares during the period. Point72 Asset Management L.P. bought a new position in shares of Natus Medical during the second quarter valued at about $23,534,000. FMR LLC increased its position in shares of Natus Medical by 4.5% in the second quarter. FMR LLC now owns 460,000 shares of the company’s stock valued at $17,388,000 after buying an additional 20,000 shares during the period. Penn Capital Management Co. Inc. bought a new position in shares of Natus Medical during the second quarter valued at about $9,979,000. Finally, BlackRock Investment Management LLC increased its position in shares of Natus Medical by 4.7% in the second quarter. BlackRock Investment Management LLC now owns 135,447 shares of the company’s stock valued at $5,120,000 after buying an additional 6,052 shares during the period. Institutional investors and hedge funds own 87.94% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.